EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real‐World Evidence From a Chinese Cohort

Tong Yi, Luwen Huang, Wei Peng, Ting Zhang, Dong Zhou, Xiaohui Lai, Jinmei Li

Brain and Behavior · 2025

DOI: 10.1002/brb3.70968 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Brain and Behavior, 2025. Verfasst von Tong Yi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Resistant Epilepsy, Nitriles, Epilepsies, Partial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness and safety of perampanel (PER) as an add‐on treatment in patients with refractory focal epilepsy.

Methods

This single‐center, retrospective observational study consecutively enrolled patients with refractory focal epilepsy who initiated PER as adjunctive therapy between September 2020 and October 2021. The primary outcomes included PER effectiveness (≥ 50% seizure reduction), treatment retention rates, and adverse event (AE) profiles, systematically evaluated at 3‐, 6‐, and 12‐month follow‐up intervals.

Results

This study included 190 patients (median age 27 years; 51.6% female). At 3/6/12‐month follow‐ups, response rates were 65.5%/64.9%/66.1%, seizure‐free rates 26.2%/26.2%/26.8%, and retention rates 88.4%/69.0%/66.8%, respectively. Logistic regression analysis indicated that females had a lower response rate (OR = 0.38, 95% CI = 0.20.74, p = 0.005). Responders had a higher PER dose (≥ 6 mg) than nonresponders at all follow‐ups. Patients receiving late add‐on PER treatment had significantly higher response and seizure‐free rate than those receiving early add‐on therapy. AEs were reported in 41.1% of patients, mostly mild to moderate in severity. The most frequent AEs were dizziness (26.3%), somnolence (13.0%), and psychiatric symptoms (12.11%). Additionally, patients aged ≥ 18 years had a lower risk of AEs (OR = 0.41, 95% CI: 0.19–0.88, p = 0.023).

Conclusions

PER demonstrated clinically meaningful efficacy and acceptable safety in refractory focal epilepsy, with sustained response rates and seizure freedom over 12 months. Male gender, higher doses, and late add‐on use predicted better outcomes, while adults experienced fewer adverse events. These real‐world findings support PER's role in treatment‐resistant cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsDrug Resistant EpilepsyNitrilesEpilepsies, PartialPyridonesHumansFemaleMaleAdultRetrospective StudiesYoung AdultAdolescentMiddle AgedTreatment OutcomeChinaDrug Therapy, CombinationEast Asian People

Stichwörter der Autor:innen

add‐on therapyeffectivenessperampanelrefractory focal epilepsysafety

Substanzen

perampanelAnticonvulsantsNitrilesPyridones

Autor:innen und Institutionen

  • Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Department of Neurology, Suining Central Hospital, Suining, Sichuan Province, China.
  • Department of Neurology, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
  • Institute of Brain Science and Brain-inspired Technology of West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zitieren

APA

Yi, T., Huang, L., Peng, W., Zhang, T., Zhou, D., Lai, X., & Li, J. (2025). Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real‐World Evidence From a Chinese Cohort. Brain and Behavior. https://doi.org/10.1002/brb3.70968

Vancouver

Yi T, Huang L, Peng W, Zhang T, Zhou D, Lai X, et al. Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real‐World Evidence From a Chinese Cohort. Brain and Behavior. 2025. doi:10.1002/brb3.70968

BibTeX
@article{Yi2025,
  author = {Yi, Tong and Huang, Luwen and Peng, Wei and Zhang, Ting and Zhou, Dong and Lai, Xiaohui and Li, Jinmei},
  title = {Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real‐World Evidence From a Chinese Cohort},
  journal = {Brain and Behavior},
  year = {2025},
  doi = {10.1002/brb3.70968}
}
Kostenlos starten →